[HTML][HTML] A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use
H Haahr, EG Fita, T Heise - Clinical pharmacokinetics, 2017 - Springer
Insulin degludec/insulin aspart (IDegAsp; 70% IDeg and 30% IAsp) is a soluble combination
of two individual insulin analogues in one product, designed to provide mealtime glycaemic …
of two individual insulin analogues in one product, designed to provide mealtime glycaemic …
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
R Mehta, R Chen, T Hirose, M John… - Diabetes, Obesity …, 2020 - Wiley Online Library
Insulin degludec/insulin aspart (IDegAsp) is a fixed‐ratio co‐formulation of insulin degludec,
which provides long‐lasting basal insulin coverage, and insulin aspart, which targets …
which provides long‐lasting basal insulin coverage, and insulin aspart, which targets …
[PDF][PDF] 德谷门冬双胰岛素临床应用专家指导意见
朱大龙， 赵维纲， 匡洪宇， 陆菊明， 杨文英， 郭立新… - 中华糖尿病杂志, 2021 - dzrmyy.cn
可溶性双胰岛素制剂德谷门冬双胰岛素制剂(IDegAsp) 含70% 德谷胰岛素和30% 门冬胰岛素,
两种组分在制剂中独立存在, 皮下注射后各自发挥作用. 为帮助临床更加合理及规范地应用 …
两种组分在制剂中独立存在, 皮下注射后各自发挥作用. 为帮助临床更加合理及规范地应用 …
[HTML][HTML] Postprandial glucose excursions in Asian versus non-Asian patients with type 2 diabetes: a post hoc analysis of baseline data from phase 3 randomised …
W Yang, S Akhtar, E Franek, M Haluzík, T Hirose… - Diabetes Therapy, 2022 - Springer
Introduction Increased postprandial glucose (PPG) is associated with high glycated
haemoglobin levels and is an independent risk factor for cardiovascular diseases. The aim …
haemoglobin levels and is an independent risk factor for cardiovascular diseases. The aim …
[HTML][HTML] The clinical role of insulin degludec/insulin aspart in type 2 diabetes: an empirical perspective from experience in Australia
SJ Glastras, N Cohen, T Dover, G Kilov… - Journal of Clinical …, 2020 - mdpi.com
Treatment intensification in people with type 2 diabetes following failure of basal insulin
commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more …
commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more …
[HTML][HTML] A Japanese study assessing glycemic control with use of IDegAsp co-formulation in patients with type 2 diabetes in clinical practice: the JAGUAR study
S Kaneko, JD da Rocha Fernandes, Y Yamamoto… - Advances in …, 2021 - Springer
Introduction The aim of this study was to evaluate the glycemic control and safety of insulin
degludec/insulin aspart (IDegAsp) co-formulation in Japanese patients with type 2 diabetes …
degludec/insulin aspart (IDegAsp) co-formulation in Japanese patients with type 2 diabetes …
Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients
T Hirose, T Awata, Y Yamamoto… - Expert Opinion on …, 2018 - Taylor & Francis
Introduction: Co-formulation of basal and bolus insulin components provides a simpler
regimen for patients with type 2 diabetes than separate basal–bolus treatment. However …
regimen for patients with type 2 diabetes than separate basal–bolus treatment. However …
Co-formulations as the first injectable in type 2 diabetes: a review of efficacy, safety, and implications in clinical practice
M John, D Gopinath, T Oommen - Dubai Diabetes and Endocrinology …, 2021 - karger.com
Background: Progression of type 2 diabetes will necessitate the use of injectable therapies
in a significant number of people. Co-formulations of degludec with liraglutide (IDegLira) …
in a significant number of people. Co-formulations of degludec with liraglutide (IDegLira) …